NJ-FREYR-SOLUTIONS
13.8.2024 07:50:33 CEST | Business Wire | Press release
Freyr, a premier global Regulatory solutions and services provider, proudly announces its distinguished placement as a Leader in the esteemed Everest Group Life Sciences Regulatory and Medical Affairs Operations PEAK Matrix® Assessment 2024. Freyr has emerged as the leader from this comprehensive evaluation of over twenty (20) global service providers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240731962821/en/
Everest Group Life Sciences and Medical Affairs Operations PEAK Matrix® Assessment 2024 (Graphic: Business Wire)
The PEAK Matrix® offers an impartial, data-driven evaluation of service and technology providers, categorizing them as Leaders, Major Contenders, or Aspirants based on their overall capabilities and market impact.
“In the rapidly evolving regulatory landscape, enterprises face a myriad of challenges, such as navigating complex compliance frameworks, ever-changing regulations, and diverse geographical needs. Consequently, enterprises are increasingly reliant on external service providers with specialized knowledge and technological expertise to manage these complexities," says Lloyd Fernandes, Practice Director at Everest Group. He added, "Freyr's extensive market presence and robust affiliate network, bolstered by its localized expertise, make it adept at navigating diverse regulatory environments. Furthermore, its comprehensive portfolio of technological solutions built on the AI first Freya Fusion platform, along with its dedicated centers of excellence, enable it to effectively address clients' digitization and efficiency demands. These strengths have contributed to its Leader positioning in Everest Group's Regulatory and Medical Affairs Operations PEAK Matrix Assessment 2024."
Suren Dheenadayaalan, CEO of Freyr Solutions, expressed his delight, stating, "Securing the Leader position in the Everest Group Life Sciences Regulatory and Medical Affairs Operations PEAK Matrix® Assessment is a significant milestone for Freyr. This recognition reaffirms our commitment throughout the Regulatory value chain in the Life Sciences sector. We take pride in being recognized as a reliable global Regulatory partner and remain committed to fostering innovation while surpassing compliance standards in the intricate Regulatory landscape."
Rajiv Rangan, Co-founder of Freyr Solutions, added, "This acknowledgment from the prestigious Everest Group underscores our continued dedication to Regulatory services & solution excellence spanning over decade+ years. On behalf of the founding team of Freyr, I extend our sincere and heartfelt gratitude to our global colleagues and customers for their continued and invaluable support, without which this accomplishment would not have been possible."
About Freyr
Freyr Solutions provides global Regulatory solutions, with 2100+ experts supporting 1550+ customers in 120+ countries.
"Discover how Freyr leads the way in regulatory excellence—visit our website for more details. Freyr Solutions"
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731962821/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release
A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th
Canva Announces Anthropic Collaboration to Bring AI-Powered Design to Millions17.4.2026 17:51:00 CEST | Press release
New collaboration brings Canva into Claude Design by Anthropic, turning AI-generated ideas into fully editable, on-brand designs Canva, the world’s leading all-in-one visual communication platform, today announced the next chapter in its two-year strategic collaboration with Anthropic, bringing Canva directly into the newly launched Claude Design by Anthropic Labs, one day after unveiling Canva AI 2.0 to a crowd of 6,500 people at Canva Create in Los Angeles.. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260410843169/en/ Canva and Claude Canva is also today introducing HTML importing, a new capability that makes it easy to bring interactive content generated in tools like Claude into the Canva editor for drag-and-drop collaboration, refinement, and publishing. The collaboration makes it easier for Claude Design users to turn AI-generated drafts and ideas into fully editable designs in Canva, where they become collaborative
Andersen Consulting tilføjer samarbejdsfirmaet Nuvolar17.4.2026 15:43:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform for digitale transformation gennem en samarbejdsaftale med Nuvolar, et teknologikonsulenthus med speciale i cloudbaseret softwareudvikling og avancerede Salesforce-implementeringer. Nuvolar, der blev stiftet i 2008 og har hovedsæde i Spanien, leverer end-to-end digital produktudvikling med dyb ekspertise inden for Salesforce, specialudviklede web- og mobilapplikationer, full-stack udvikling, UX/UI-design, produktledelse og langsigtede supporttjenester. Med mere end 110 fagfolk fordelt over Barcelona, Madrid, Miami og Mexico City arbejder virksomheden med kunder inden for luftfart, sundhedsvæsen, forbrugsgoder, medicinalindustrien samt hotel- og restaurationsbranchen for at designe og implementere skalerbare, forretningskritiske platforme, der optimerer driften og fremskynder den digitale transformation. "Samarbejdet med Andersen Consulting giver os mulighed for at levere vores ekspertise i en større skala," udtalte Marc Vivas, administrerende di
Qualcomm Announces Quarterly Cash Dividend17.4.2026 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.92 per common share, payable on June 25, 2026, to stockholders of record at the close of business on June 4, 2026. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business
Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 202617.4.2026 13:00:00 CEST | Press release
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate antibody-drug conjugate (ADC) technology platforms in poster sessions at the American Society for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA, from today through to 22 April. Wim Dokter, PhD, Chief Scientific Officer at Byondis, said: “The research we are presenting at AACR highlights the potential of two of our state-of-the-art ADC technology platforms to address significant limitations with current therapeutic approaches in cancer treatment. Our first-in-class antifolate linker-drug platform features an orthogonal mechanism of action based on clinically validated biology. This approach is engineered to address acquired resistance that can develop with current ADC treatments, positioning it for use across treatment lines. Our phosphonate linker-drug platform offers a complementary me
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom